<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Animal and clinical studies have demonstrated that <z:mp ids='MP_0003674'>oxidative stress</z:mp>, a common pathophysiological factor in <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e>, reduces repolarization reserve by enhancing the L-type calcium current, the late Na, and the Na-Ca exchanger, promoting early afterdepolarizations (EADs) that can initiate <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> and <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) in structurally remodeled hearts </plain></SENT>
<SENT sid="1" pm="."><plain>Increased ventricular <z:mp ids='MP_0003045'>fibrosis</z:mp> plays a key facilitatory role in allowing <z:mp ids='MP_0003674'>oxidative-stress</z:mp> induced EADs to manifest as triggered activity and VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, since <z:mpath ids='MPATH_458'>normal</z:mpath> non-fibrotic hearts are resistant to <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> when challenged with similar or higher levels of <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The findings imply that antifibrotic therapy, in addition to therapies designed to suppress EAD formation at the cellular level, may be synergistic in reducing the risk of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
</text></document>